The latest price target for Bluejay Diagnostics (NASDAQ:BJDX) was reported by Dawson James on August 3, 2023. The analyst firm set a price target for $0.00 expecting BJDX to fall to within 12 months (a possible -100.00% downside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for Bluejay Diagnostics (NASDAQ:BJDX) was provided by Dawson James, and Bluejay Diagnostics downgraded their neutral rating.

There is no last upgrade for Bluejay Diagnostics

The last downgrade for Bluejay Diagnostics Inc happened on August 3, 2023 when Dawson James changed their price target from N/A to N/A for Bluejay Diagnostics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Bluejay Diagnostics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Bluejay Diagnostics was filed on August 3, 2023 so you should expect the next rating to be made available sometime around August 3, 2024.

While ratings are subjective and will change, the latest Bluejay Diagnostics (BJDX) rating was a downgraded with a price target of $0.00 to $0.00. The current price Bluejay Diagnostics (BJDX) is trading at is $4.20, which is out of the analyst’s predicted range.